LINGO1抗体;LINGO1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12771(LINGO1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12771(LINGO1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

LINGO-1 (Leucine-rich repeat and immunoglobulin domain-containing protein 1) is a transmembrane protein predominantly expressed in the central nervous system (CNS), particularly in neurons and oligodendrocytes. It functions as a key component of the Nogo receptor complex, which negatively regulates neuronal growth, axon regeneration, and myelination. LINGO-1 interacts with signaling pathways such as the RhoA/ROCK cascade, inhibiting oligodendrocyte differentiation and myelination while promoting neuronal apoptosis. Its role in suppressing CNS repair mechanisms has made it a therapeutic target for demyelinating diseases like multiple sclerosis (MS) and spinal cord injuries.

Anti-LINGO-1 antibodies are designed to block LINGO-1 activity, aiming to enhance remyelination and neuroprotection. Preclinical studies demonstrated that LINGO-1 inhibition promotes oligodendrocyte maturation, axon regeneration, and functional recovery in animal models of MS and nerve injury. Clinical trials explored humanized anti-LINGO-1 antibodies (e.g., opicinumab) as potential MS therapies, though mixed results in phase II trials highlighted challenges in balancing efficacy and dosing. Emerging research also links LINGO-1 polymorphisms to Parkinson’s disease risk, expanding its potential therapeutic relevance. While clinical translation remains ongoing, LINGO-1 antibodies represent a novel strategy to address unmet needs in neurodegenerative and neuroinflammatory disorders by targeting intrinsic repair pathways.